Biotechnology

EU EFSA Opens Public Consultation on NZYM-FS Cellulase Food Enzyme

EFSA has opened a short public consultation on an application to authorise cellulase (CAS 9012-54-8) from a genetically modified Trichoderma reesei strain NZYM-FS as a new food enzyme under the EU Food Enzymes Regulation, while its risk assessment remains ongoing and subject to an EFSA deadline of 4 December 2026. For enzyme manufacturers and food producers this signals continued progress but no authorisation yet; key dates to monitor are the consultation window to 29 April 2026, the current clock-stop end expected on 26 June 2026, and the overall EFSA assessment deadline later in 2026.

10 Apr 2026, 15:51open.efsa.europa.euEuropean Union

Argentina Adopts Resolution 24/2026 Updating ICP Procedures for New Breeding Techniques

Argentina has updated its regulatory framework for New Breeding Techniques (NBT) through Resolution 24/2026, streamlining the process for determining if biotech-derived organisms are classified as GMOs. This shift reduces administrative burdens and timelines for developers, reinforcing a science-based, pro-innovation environment for agricultural biotechnology in the region.

5 Apr 2026, 19:01boletinoficial.gob.arArgentina

EU EESC Adopts Opinion on European Biotech Act Proposal

The EESC adopted its opinion on the European Biotech Act in March 2026, supporting the framework while advocating for stricter licensing and biosafety oversight. Companies should anticipate potential new mandates for 'biotechnology products of concern' and enhanced traceability for GMO-derived materials in the supply chain.

5 Apr 2026, 05:18data.consilium.europa.euEuropean Union

U.S. GAO Highlights Regulatory Gaps for Engineered Biofertilizers

The U.S. GAO has highlighted significant regulatory gaps for engineered biofertilizers, warning that existing frameworks are poorly equipped to manage genetically engineered microbes. Stakeholders should anticipate future legislative or agency efforts to clarify definitions and jurisdiction, which will directly impact the approval timelines and compliance strategies for microbial soil products.

5 Apr 2026, 05:04gao.govUnited States

US House Introduces Bioindustrial Scale-Up for Supply Chains and Energy Resiliency Act of 2026 (H.R. 7936)

The US House introduced H.R. 7936 in March 2026 to accelerate the commercialization of bioindustrial manufacturing and strengthen domestic supply chains for chemicals and energy materials. This proposal signals a shift toward federally supported, open-access infrastructure for scaling biotechnology, offering manufacturers new pathways to transition from fossil-based to bio-based feedstocks.

4 Apr 2026, 10:32govinfo.govUnited States

Germany (BAuA) Issues 4th Amendment to TRBA 468 Cell Line List

Germany's BAuA has updated TRBA 468, revising the classification of specific cell lines and restructuring the technical list for biological agents. Operators must update risk assessments and safety documentation for cell culture activities to ensure compliance with revised protection levels and viral infection data.

3 Apr 2026, 09:55baua.deGermany

Germany Revises TRBA 466 On Classification Of Prokaryotes Into Risk Groups

Germany has updated the technical rule (TRBA 466) for classifying bacteria and archaea into risk groups, effective March 2026. Businesses must review the revised species list to update workplace risk assessments and ensure containment measures meet the latest occupational safety standards.

3 Apr 2026, 09:50baua.deGermany

Denmark Consults on EU Amendment to Rebaudioside M (E 960c(ii)) Specifications

The EU is expanding the permitted manufacturing routes for Rebaudioside M (E 960c(ii)) while introducing new purity limits for kaurenoic acid. This update provides greater sourcing flexibility for steviol glycosides but requires manufacturers to validate supply chain compliance against the revised purity and production specifications.

2 Apr 2026, 17:42prodstoragehoeringspo.blob.core.windows.netDenmarkEuropean Union

EU EFSA Panel Evaluates Extension Of Use For Food Enzyme Glucan 1,4‑α‑Maltohydrolase (NZYM‑SD)

EFSA has issued a positive safety opinion for extending the use of the food enzyme glucan 1,4-α-maltohydrolase to five food manufacturing processes, including plant-based milk analogues. This assessment clears a major technical hurdle for expanded market access and provides regulatory certainty for manufacturers using this enzyme in diverse food categories.

2 Apr 2026, 17:04efsa.onlinelibrary.wiley.comEuropean Union

Estonia Establishes Fast-Track Clinical Trial Assessment Procedure and Joins FAST-EU Pilot

Estonia has launched a national fast-track assessment for Phase I/II clinical trials and joined the EU-wide FAST-EU pilot to accelerate drug development timelines. Pharmaceutical and biotech firms can now leverage shorter 30–40 day review windows in Estonia, signaling a broader European shift toward more competitive and streamlined market entry for innovative medicines.

2 Apr 2026, 16:59ravimiamet.eeEstoniaEuropean Union

EFSA Registers Novel Food Application for Cell-Cultured Bovine Fat Biomass (Bos taurus)

EFSA has commenced the suitability check for a novel food application for cell-cultured bovine fat biomass, marking a formal step toward EU market access for cultivated meat components. This development signals the beginning of a multi-year risk assessment process that will set safety precedents for the alternative protein industry and future hybrid food products.

2 Apr 2026, 10:18open.efsa.europa.euEuropean Union

Louisiana SB 434 Would Treat Foods Containing Vaccines as Drugs

Louisiana SB 434 proposes reclassifying foods containing vaccines as "drugs" under state law, with potential implementation by August 2026. This shift would subject edible vaccine products to pharmaceutical-grade manufacturing and labeling standards, significantly increasing compliance complexity for biotechnology and novel food developers.

1 Apr 2026, 19:48legis.la.govUnited States

EU Commission Updates Union List of Novel Foods With New Authorisations and Akkermansia Labelling Changes

The EU has expanded its Union list of novel foods with new authorisations for rapeseed powder and lacto-N-tetraose, while tightening labelling and use conditions for pasteurised Akkermansia muciniphila. Manufacturers must align product formulations and marketing claims with these specific legal specifications to maintain market access and ensure compliance with updated probiotic safety standards.

1 Apr 2026, 19:45food.ec.europa.euEuropean Union

Canada Approves Genetically Engineered PRRSV-Resistant Pigs For Food And Feed

Canada approved genetically engineered PRRSV-resistant pigs for food and feed use in January 2026. This alignment with major trading partners facilitates biotech adoption in the food supply chain and confirms that no special labeling is required for these gene-edited products.

1 Apr 2026, 14:42canada.caCanada

EU Commission Working Document on Proposal To Amend Directives 2001/18/EC and 2010/53/EU on Genetically Modified Microorganisms and Organ Processing

The European Commission has detailed proposed authorization pathways for organ processing and genetically modified microorganisms under the forthcoming Biotech Act. The shift toward a centralized EU list of authorized technologies signals a move to streamline market access and reduce administrative barriers for medical and biotech operators.

1 Apr 2026, 14:32data.consilium.europa.euEuropean Union

US House Introduces FAIR Act (H.R. 7953) on Reciprocal Rare Disease Drug Approvals

The US House introduced the FAIR Act (H.R. 7953) to establish reciprocal marketing approval pathways for rare disease therapies authorized by trusted foreign regulators. This proposal signals a shift toward international regulatory harmonization, potentially accelerating US market entry for innovative drugs and biologics.

1 Apr 2026, 14:17govinfo.govUnited States

Italy AIFA Classifies Steqeyma (Ustekinumab) In Provisional Reimbursement Class C(nn)

Italy's AIFA has provisionally classified the biosimilar Steqeyma (ustekinumab) in reimbursement class C(nn), effective March 29, 2026. Marketing authorization holders must adhere to strict pricing notification and reimbursement application timelines to prevent mandatory price alignment to the lowest class level.

1 Apr 2026, 14:16gazzettaufficiale.itItaly

US House Introduces AI-Ready Bio-Data Standards Act (H.R. 7907)

The US House introduced the AI-Ready Bio-Data Standards Act to establish NIST-led standards for biological datasets used in artificial intelligence. Organizations in biotechnology and biomanufacturing should anticipate new data management and cybersecurity obligations that will likely become prerequisites for federal research funding and procurement.

1 Apr 2026, 14:15govinfo.govUnited States

European Commission Answer Outlines Availability Obligations for Gene Therapies and Links to Critical Medicines Act Proposal

The European Commission has signaled that upcoming pharmaceutical reforms and the Critical Medicines Act will introduce mandatory supply obligations and collaborative procurement for high-priority therapies. Companies face the risk of losing market protection if products are not made available within three years, necessitating a strategic review of EU-wide launch and distribution plans.

31 Mar 2026, 19:21europarl.europa.euEuropean Union

US Senate Introduces Bill On Logbooks For Distributors Of Highly Pathogenic Agents

The US Senate has introduced legislation (S.4227) to mandate strict logbook and recordkeeping requirements for distributors of highly pathogenic biological agents. Businesses in the biotechnology and life sciences sectors should prepare for enhanced traceability obligations and federal oversight of high-risk pathogen supply chains.

29 Mar 2026, 17:55congress.govUnited States